MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why QNRX Stock advanced +0.97% Today — RQD Quant Desk Flash
$4.15 +0.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.15
Quoin Pharmaceuticals Ltd. (QNRX) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $19.9M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.15 (-0.02%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-4.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QNRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY QNRX SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (31% of score)
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 49.3 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (23% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$4.50-13.3% Next Q
56
Q2 (-2Q)Grade C-$3.90+3.1% Next Q
53
Q3 (-1Q)Grade C-$4.02+3.2% Next Q
51
CurrentGrade D$4.15-5.6% Hist 90D α
48
Trajectory: C (56) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a QNRX Turnaround Squeeze
While QNRX currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.43) and Max Pain ($4.36) forces dealer call-delta covering toward $24.68.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $QNRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QNRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why QNRX Stock advanced +0.97% Today — RQD Quant Desk Flash
Quoin Pharmaceuticals Ltd. (QNRX) advanced +0.97% to $4.15, trading at 4% of its 52-week range ($3.25 – $23.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($3.25 – $23.5) with RSI-14 at 49.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.15 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live QNRX Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QNRX)
- ✓Walkthrough of QNRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
QNRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.96%🛡️ HOLDING TREND SUPPORT
2026-10-30O $4.19H $4.54L $3.87C $4.15VOL 36.6K
RES: $9.13SUP: $3.86SMA50: $5.43SMA200: $6.05
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
QNRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on QNRX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for QNRX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QNRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QNRX)
Health Care Rank #392 of 1016
⚔️ KPTI vs QNRX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (QNRX vs. KPTI, MCRB, ACTU, QNTM)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Quoin Pharmaceuticals Ltd. (QNRX) ranks #392 by composite RQD confidence (48/100, grade D) and #835 by equity capitalization ($19.9M). Within this direct 5-issuer industry benchmark cohort, QNRX leads on earnings valuation at N/A trailing P/E, while QNRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. QNTM currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with QNRX at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| QNRX
ACTIVE
Quoin Pharmaceuticals Ltd. | D | 48/100 | — | — | -35.0% | +0.97% | $19.9M | Benchmark Subject |
| KPTI Karyopharm Therapeutics Inc. | D | 47/100 | — | — | -35.0% | +5.73% | $20.0M | /kpti-vs-qnrx → |
| MCRB Seres Therapeutics Inc. | D+ | 54/100 | — | — | -35.0% | +8.94% | $19.6M | /mcrb-vs-qnrx → |
| ACTU Actuate Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | -3.21% | $20.4M | /actu-vs-qnrx → |
| QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares | D+ | 58/100 | — | — | — | +2.95% | $20.7M | /qntm-vs-qnrx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001671502In its most recent audited fiscal period (FY2025, filed 2025-12-31), Quoin Pharmaceuticals Ltd. (QNRX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$15.8M, operating cash flow of -$13.5M, and free cash flow of -$13.5M (-72.3% YoY). On the balance sheet, QNRX closed FY2025 with $20.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$15.8M | -$13.5M | -$13.5M | $20.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$9.0M | -$7.9M | -$7.9M | $15.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$8.7M | -$7.9M | -$7.9M | — | — |
3. QNRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs QNRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $4.15 (+0.97% 1D, market cap $19.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, QNRX ranks #392 in composite RQD confidence.
How does QNRX compare to KPTI and MCRB in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QNRX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KPTI (Karyopharm Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $20.0M) and MCRB (Seres Therapeutics Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -35.0%, cap $19.6M). Among the 5-stock peer group, QNRX leads on earnings multiple (N/A) while QNRX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for QNRX?
Per QNRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671502), Quoin Pharmaceuticals Ltd. generated $0 in revenue, -$15.8M in net income, and -$13.5M in free cash flow against $20.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is QNRX trading relative to its 50-day, 200-day, and 52-week technical levels?
QNRX last traded at $4.15 (+0.97% on volume of 3,344 shares), positioning the stock -23.57% below its 50-day simple moving average ($5.43) and -31.40% below its 200-day simple moving average ($6.05). Across its 52-week range of $3.25 to $23.50, QNRX sits at the 4.4% percentile with a 14-day RSI of 49.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.63 to $4.67).
QNRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is QNRX stock moving today?
Why QNRX Stock advanced +0.97% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.